NeuBase Therapeutics Inc (NAS:NBSE)

$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 33/100

NeuBase Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
NeuBase Therapeutics Inc Corporate Update Call Transcript
May 22, 2023
NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
Oct 03, 2022
NeuBase Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 10, 2022
NeuBase Therapeutics Inc Data Call Transcript
Mar 14, 2022
NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
NeuBase Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
NeuBase Therapeutics Inc Accelerating the Genetic Revolution with a New Class of Synthetic Medicines Transcript
Dec 23, 2020
NeuBase Therapeutics Inc Myotonic Dystrophy Type 1 Data Webinar Transcript
Dec 16, 2020
NeuBase Therapeutics Inc at Manufacturing Heat-Seeking Missiles Against Misbehaving Transcript
Oct 29, 2020
NeuBase Therapeutics Inc Tribe Public's Presentation and Q&A Webinar Event Transcript
Oct 28, 2020
NeuBase Therapeutics Inc Industry Updates Friday Transcript
Oct 06, 2020
NeuBase Therapeutics Inc to Present at Tribe Public's Presentation and Q&A Webinar Transcript
Aug 26, 2020

NeuBase Therapeutics Inc Data Call Transcript

Mar 14, 2022 / 12:00PM GMT

Release Date Price: $28.6 (-4.67%)

Transcript

Operator

Greetings. Welcome to the NeuBase Therapeutics Investor Update Call. (Operator Instructions) Please note this conference is being recorded.

At this time, I'll turn the conference over to Todd Branning, Chief Financial Officer. Todd, you may now begin.

Todd P. Branning

NeuBase Therapeutics, Inc. - CFO

Thank you, moderator. Good morning, everyone, and welcome to NeuBase's investor update call. I'm Todd Branning, Chief Financial Officer at NeuBase.

I am joined today by Dr. Dietrich Stephan, our Chief Executive Officer; and Dr. Sandra Rojas-Caro, our Chief Medical Officer. During today's call, Dietrich will deliver introductory remarks and provide some general context, and Sandra will provide an update on our myotonic dystrophy type 1, or DM1, development program. Then we will open the call for your questions. We expect this call to last 45 minutes.

I would like to remind you that this call will contain remarks concerning NeuBase's future expectations, plans and prospects, which constitute forward-looking statements for the purposes of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.